Fed. Circ. Won't Stay Vimovo Case Despite Looming Generic
The Federal Circuit won't stay its finding that two patents covering Horizon Pharma Inc.'s Vimovo are invalid while the drugmaker appeals to the U.S. Supreme Court, even if it means Dr....To view the full article, register now.
Already a subscriber? Click here to view full article